In real-world studies, biosimilar CT-P6 demonstrated pCR comparable to reference trastuzumab (CT-P6: 74.4% vs. 69.8%, p = 0.411) in HER2-positiveearly-stage breast cancer [31], while SB3 showed a pCR rate comparable to that seen in previous clinical studies [32]. Here, ERBB2 is linked to breast cancer.